title: Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity.
abstract: Doxorubicin (DXR) conjugated to murine monoclonal antibodies (MoAb) raised against human breast tumor cells demonstrated a MoAb-specific, molar ratio-dependent in vitro cytotoxicity. These conjugates were prepared on a scale sufficient to allow for subsequent clinical trials (1 to 3 g of MoAb per conjugation reaction). The conjugation reaction proceeded via an N-hydroxysuccinimide (NHS) active ester intermediate of cis-aconityl-DXR (CA-DXR), resulting in a cis-aconitate acid-sensitive linker between the DXR and MoAb. Molar ratios of DXR to MoAb ranged from 40 to 45. The immunoreactivity of conjugated MoAb was only slightly decreased from naked MoAb. When immunoconjugates were incubated with MoAb-reactive tumor cells for 3 hours, specific cell-killing was observed. If the exposure time was lengthened to 18 hours, however, nonspecific killing resulted. Incubation of the immunoconjugate with the nonspecific adsorbant Amberlite XAD-2 caused an average 30% decrease in the DXR-to-MoAb molar ratio, suggesting a population of drug that is tightly but noncovalently associated with MoAb.
authors.affiliation: Biotherapeutics Inc., Franklin, TN 37065.
authors.forename: J R
authors.initials: JR
authors.lastname: Ogden
authors.forename: K
authors.initials: K
authors.lastname: Leung
authors.forename: S A
authors.initials: SA
authors.lastname: Kunda
authors.forename: M W
authors.initials: MW
authors.lastname: Telander
authors.forename: B P
authors.initials: BP
authors.lastname: Avner
authors.forename: S K
authors.initials: SK
authors.lastname: Liao
authors.forename: G B
authors.initials: GB
authors.lastname: Thurman
authors.forename: R K
authors.initials: RK
authors.lastname: Oldham
mesh_terms: D000327:Adsorption; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D055598:Chemical Phenomena; D002621:Chemistry; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D051379:Mice; D012117:Resins, Synthetic / Q000493:pharmacokinetics; D013388:Succinimides; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D004338:Drug Combinations; D012117:Resins, Synthetic; D013388:Succinimides; C062167:aconityldoxorubicin; D004317:Doxorubicin; C046797:amberlite; C001426:N-hydroxysuccinimide